Trials / Completed
CompletedNCT00506298
Study of CRx-401 on Glucose Levels in Subjects With Type II Diabetes
A Randomized, Multi-Center Study to Compare the Effects of CRx-401 to Bezafibrate Plus Placebo on Plasma Glucose Levels When Given to Subjects With Type II Diabetes on Metformin.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Zalicus · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This trial will assess the efficacy of CRx-401 in lowering FPG levels in patients taking metformin to treat their diabetes. In addition, this initial trial will evaluate insulin resistance (HOMA-IR index), HgbA1c levels, glycated protein, LDL, HDL, triglycerides, and total cholesterol, as well as the safety of CRx-401.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bezafibrate + diflunisal | bezafibrate + diflunisal |
| DRUG | bezafibrate + placebo | bezafibrate + placebo |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2009-04-01
- Completion
- 2009-05-01
- First posted
- 2007-07-25
- Last updated
- 2009-05-13
Locations
18 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00506298. Inclusion in this directory is not an endorsement.